Fundamental Analysis of ARCT
Arcturus Therapeutics is a clinical-stage biotechnology company focused on RNA-based medicines, with a proprietary LUNAR lipid delivery platform. The company operates in a high-risk, high-reward sector, developing mRNA therapeutics for rare diseases (LUNAR-OTC for OTC deficiency, LUNAR-CF for cystic fibrosis) and vaccines (LUNAR-COV19, LUNAR-FLU). Its valuation has collapsed from a 52-week high of $24.17 to $7.52, reflecting a sharp decline in revenue and increased losses. As of the latest TTM data, revenue is approximately $23.8 million, but the company is deeply unprofitable with a net margin of -391.9%, an operating margin of -433.4%, and EBITDA margin of -348.4%. The balance sheet, however, is relatively strong with $191.5 million in cash (per Q2 2026) and minimal debt (debt-to-equity of 13.3%), providing a runway into 2026. Key metrics show a current ratio of 5.879, quick ratio of 5.879, and a book value per share of $6.05, suggesting the stock trades at a slight premium to tangible book (price-to-book of 1.24). The company's R&D spending is massive relative to revenue (362.1% of revenue), reflecting its investment in clinical trials. Recent catalysts include promising Phase 2 data for ARCT-032 in cystic fibrosis, and partnerships with Janssen, Ultragenyx, and CureVac. However, revenue has drastically declined from previous COVID-related vaccine contracts, and the company faces significant dilution risk, regulatory hurdles, and competition. Analyst consensus is cautiously optimistic, with the stock receiving a 'Buy' rating from several analysts, though the short-term outlook is uncertain given ongoing losses and cash burn. The long-term potential hinges on successful clinical trial outcomes and commercialization of its rare disease pipeline.
